Novartis AG (NVS) on Thursday reported positive results from the biomarker cohort of the FORTITUDE Phase I/II study evaluating del-brax in patients with Facioscapulohumeral Muscular Dystrophy (FSHD).
The FORTITUDE Phase I/II trial is assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of del-brax in FSHD patients.
Cohort C of the study evaluated del-brax administered every six weeks versus placebo over a 12-month period in patients aged 16 to 70 years. The study met its primary and key secondary endpoints, demonstrating reductions in KHDC1L and creatine kinase levels, while maintaining a safety profile consistent with previous findings.
The Phase III FORTITUDE-3 study of del-brax is currently underway.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.